Gilgamesh is a preclinical biotechnology company focused on serious mental health science. They are working on innovative new chemical entities (NCE’s), bringing together medicinal chemistry, neuroscience & neurobiology, drug development expertise, and intellectual property strategy.
Gilgamesh
The company is developing oral arylcyclohexylamine and next-generation psychedelics for mental health and other impairments such as Treatment-Resistant Depression (TRD), opiate use disorder (SUD), ADHD, and depression with cognitive impairment.
Gilgamesh has raised a total of $29.6 million in funding over 5 rounds. Their latest funding was raised on May 6th, 2021 from a Series A round.
“The next generation of central nervous system drugs inspired by psychedelic medicines”
Key staff
- Johnathan Sporn – Founder & CEO
- Andrew Kreugel – Co-founder & Head of Chemistry
- Gerard Marek – CMO
Media
Activities
B2B
Biotech
Drug Discovery
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Gilgamesh Announces Clinical Candidates For Two Programs With First In Human Dosing to Begin in Late 2022 (Biospace, 24 March 2022)Drug companies are investing big in psychedelics, but can they engineer out the trip? (Chemical & Engineering News, 06 March 2022)